This study discovers an essential role of Cdk1-TAZ signalling in determining the tumor cell sensitivity to antitubulin drugs and suggests a novel signalling target for the treatment of antitubulin drug-resistant cancers. This evidence concerns the gene CDK1 and neoplasm.